ErinRenee(Olson)MacraeMD

Oncology • Columbus, OH

Physician

Join to view full profile

Dr. Macrae is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Macrae's full profile

Already have an account?

Office
810 Jasonway Ave
Ste A
Columbus, OH 43214
Phone+1 614-442-3130

Fax+1 614-442-3145

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2011
University of Pennsylvania Health SystemResidency, Internal Medicine, 2005 - 2008
Case Western Reserve University School of MedicineClass of 2005

Certifications & Licensure

OH State Medical License 2011 - 2026
PA State Medical License 2005 - 2008
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
Active, not recruiting
Phase 2
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Start of enrollment: 2013 Oct 02
Completed
Phase 2
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) Start of enrollment: 2015 Aug 12
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Vishnu Prasath, Hinda Boutrid, Robert Wesolowski, Mahmoud Abdel-Rasoul, Cynthia Timmers
Breast Cancer Research and Treatment. 2024-12-07
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
Dionisia Quiroga, Robert Wesolowski, Sara Zelinskas, Ashley Pinette, Brooke Benner
Cancer Control. 2024-05-27
117 citations
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Harold J. Burstein, Mark R. Somerfield, Debra L. Barton, Ali Dorris, Lesley Fallowfield
Journal of Clinical Oncology. 2021-07-29

Press Mentions

Examples Help Breast Cancer Patients UnderstandMarch 31st, 2017